Newcardio, Inc. (NWCI)

[califax]

NewCardio's Chief Medical Officer, Dr. Ihor Gussak, to Present at Prestigious Cardiac Electrophysiology Conference in Tokyo

Date : 02/04/2010 @ 8:00AM
Source : PR Newswire
Stock : (NWCI)

http://ih.advfn.com/p.php?pid=nmona&article=41396179&symbol=NWCI

NewCardio's Chief Medical Officer, Dr. Ihor Gussak, to Present at Prestigious Cardiac Electrophysiology Conference in Tokyo

Dr. Gussak to Provide Special Lecture at the Japanese Idiopathic Ventricular Fibrillation (J-IVFS) Annual Meeting on February 8, 2010

SAN JOSE, Calif., Feb. 4 /PRNewswire-FirstCall/ --

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced today that its Chief Medical Officer, Ihor Gussak MD, PhD, FACC, world-recognized expert in electrocardiology and cardiac safety, will provide a special lecture at the prestigious Japanese Idiopathic Ventricular Fibrillation (J-IVFS) Annual Meeting at the Sankei Plaza convention center in Tokyo, Japan on February 8, 2010. Dr. Gussak's presentation, Early Ventricular Repolarization: ECG Phenomena and Arrhythmogenic Potentials" will be Chaired by Prof. Kaoru Sugi (Toho University Ohashi Medical Center)

The 45-minute presentation will show how a three-dimensional (3D) ECG analysis, made possible by NewCardio's technology, provides additional information on subtle or non-conclusive changes, which clinicians can use to assess risk of sudden cardiac arrest more appropriately and effectively. NewCardio's platform technology, which applies advanced 3D techniques and modern computer software, can help clinicians to identify patients at risk of fatal arrhythmias by providing clinicians a deeper look and additional information compared to traditional techniques

"NewCardio remains committed to deploying state-of-the-art science and technology to enable more accurate diagnosis and risk stratification of serious cardiac conditions and to advance the prevention and treatment of life-threatening conditions, including electrical diseases of the heart," commented Dr. Gussak. "I am excited to share our latest developments and discuss the far-reaching potential of our platform technology at the J-IVFS."

The J-IVFS is one of the most prestigious Cardiac Electrophysiology events in the world, covering areas of particular focus in Japan where idiopathic sudden cardiac arrest is endemic and very problematic. Distinguished attendees at the event include Dr. Masakazu Hiraoka (Ministry of Health, Labor and Welfare, Labor Health Appeal Committee), Professor Kazutaka Aonuma (University of Tsukuba), Naohiko Aihara (National Cardiovascular Center), Dr. Masahiko Takagi (Osaka City University Graduate School of Medicine), Dr. Yukio Sekiguchi (University of Tsukuba), Dr.Yasuhiro Yokyama (National Disaster Medical Center), Professor Hirotsugu Atarashi (Nihon Medical University Tama Nagayama Hospital) and Dr. Akihiko Nogami (Yokohama Rosai Hospital), and Dr. Sami Viskin (Israel)

Dr. Gussak is a Fellow of the American College of Cardiology, and serves on the Clinical Cardiology Council of the American Heart Association. He is a member of the American Academy of Pharmaceutical Physicians, the International Cardiac Electrophysiology Society, the International Society for Holter and Noninvasive Electrocardiology, the Drug Information Association, and the International Scientific Committee on Arrhythmogenic Right Ventricular Dysplasia-Cardiomyopathy. He has published several textbooks and numerous peer-reviewed articles on these and other subjects in clinical cardiology

NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's lead product is QTinno(TM), a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development

About NewCardio, Inc

NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit http://www.newcardio.com/

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Investor Contact: Hayden IR Jeff Stanlis, Partner [phone]

DATASOURCE: NewCardio, Inc

CONTACT: Investors, Jeff Stanlis, Partner at Hayden IR, [phone],

, for NewCardio, Inc

Web Site: http://www.newcardio.com/